TMO
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc historical holders
total: 22
Matrix Advisors Value Fund Thermo Fisher Scientific Inc transactions over time
- Total transactions:
- 8
- New positions:
- 1
- Added:
- 2
- Reduced:
- 5
- Held since:
- 2020 Q1
- Held for:
- 20 quarters
- Latest activity:
- 2023 Q1
David Katz has been an institutional investor in Thermo Fisher Scientific Inc (TMO) since 2020 Q1. According to 2024 Q4 report, David Katz holds 3,000 shares with a market value of roughly $1.56M representing 2.21% of their equity portfolio. The fund/company first acquired TMO in 2020 Q1, initially purchasing 4,700 shares. Since the initial investment, Matrix Advisors Value Fund has made 7 more transactions in this position.
Does David Katz still hold TMO?
Yes, David Katz continues to hold Thermo Fisher Scientific Inc (TMO). According to their 2024 Q4 report, they maintain a position of 3,000 shares valued at approximately $1.56M, representing 2.21% of their equity portfolio.
When did David Katz first invest in TMO?
David Katz first invested in Thermo Fisher Scientific Inc (TMO) in 2020 Q1 at the reported quarter-end price of $283.60 per share, acquiring 4,700 shares in their initial purchase.
What is David Katz's average cost basis for TMO?
Based on historical transaction data, David Katz's estimated cost basis for Thermo Fisher Scientific Inc (TMO) is approximately $297.59 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $297.59
- Weighted AVG sell price:
- $447.53
TMO transactions history by Matrix Advisors Value Fund
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q1
|
3.15%
|
3,000
|
$576.37
|
$1,729,110
|
-6.25% (-200)
|
-0.23%
|
|
2022 Q1
|
2.87%
|
3,200
|
$590.65
|
$1,890,080
|
+5.79% (+175)
|
+0.16%
|
|
2021 Q4
|
2.87%
|
3,025
|
$667.24
|
$2,018,401
|
-3.97% (-125)
|
-0.12%
|
|
2021 Q2
|
2.44%
|
3,150
|
$504.47
|
$1,589,080
|
+2.27% (+70)
|
+0.05%
|
|
2020 Q4
|
2.67%
|
$465.78
|
-17.54% (-655)
|
|||
|
2020 Q3
|
3.48%
|
$441.52
|
-5.44% (-215)
|
|||
|
2020 Q2
|
2.97%
|
$362.34
|
-15.96% (-750)
|
|||
|
2020 Q1
|
3.37%
|
$283.60
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.